New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
October 24, 2012
07:26 EDTETRMEnteroMedics reports Q3 (13c) vs (26c) in Q3 of 2011
Reports Q3 R&D expenses of $2.6M and G&A expenses of $3M.
News For ETRM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 14, 2015
14:07 EDTETRMEnteroMedics price target raised to $5 from $4 at Craig-Hallum
Subscribe for More Information
10:39 EDTETRMEnteroMedics confirms FDA approval of VBLOC obesity treatment
Subscribe for More Information
10:21 EDTETRMEnteroMedics obesity device approved by FDA
The FDA approved the Maestro Rechargeable System for certain obese adults, the first weight loss treatment device that targets the nerve pathway between the brain and the stomach that controls feelings of hunger and fullness. The Maestro Rechargeable System, the first FDA-approved obesity device since 2007, is approved to treat patients aged 18 and older who have not been able to lose weight with a weight loss program, and who have a body mass index of 35 to 45 with at least one other obesity-related condition, such as type 2 diabetes. The Maestro Rechargeable System is manufactured by EnteroMedics. As part of the approval, the manufacturer must conduct a five year post approval study that will follow at least 100 patients and collect additional safety and effectiveness data including weight loss, adverse events, surgical revisions and explants and changes in obesity-related conditions.
10:17 EDTETRMEnteroMedics trading halted, pending news

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use